Amyloidosis

The following summary is "Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis " published in the ...

BCMA-CART cells offer the first proof-of-concept that this therapy can treat patients with advanced RR AL in a msafe and effective manner. All 4 patients could keep their responses throughout the follow-up period, which lasted a median of 5.2 (2.5–9.5) months. The treatment was found to be reasonably safe, with only 2 patients experiencing a mild grade 3 cytokine release syndrome that lasted only a short amount of time and was easily managed and with no patients showing any signs of neurotoxicity.